Csl Behring Gmbh

Csl Limited

Westfaelische Wilhelms-Universitaet Muenster

Julius-Maximilians-Universitaet Wuerzburg

Westfalische Wilhelms-Universität Münster

Christoph Kleinschnitz

Marc Nolte

Stefan Schulte

Gerhard Dickneite

Ingo Pragst

Brent Steven McKenzie

Bernhard Nieswandt

Guido Stoll

Sven Meuth

Anna-Leena Sirén

Christiane Albert-weissenberger

Sarah Hopp-kraemer

Kerstin Goebel

Anna-Leena Siren

Brent Mckenzie

Christiane Albert-Weissenberger

Sarah Hopp-Kraemer

The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).

Therapy using a factor XII inhibitor in a neurotraumatic disorder

This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.

Factor XII inhibitors for the treatment of neurological inflammatory disorders

The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

Use of C1-inhibitor for the treatment of secondary edema of the central nervous system

Growing community of inventors

Hettstadt, Germany

Christoph Kleinschnitz